Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$18.79 USD
+0.06 (0.32%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $18.77 -0.02 (-0.11%) 6:10 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Brokerage Reports
Arcturus Therapeutics Holdings Inc. [ARCT]
Reports for Purchase
Showing records 21 - 40 ( 141 total )
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap: Priority Shifts Back to OTC, CF Programs; CSL Takes COVID-19, Funds BARDA Contract; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
CSL Acquires License to STARR, LUNAR, and mRNA Manufacturing Expertise in Sizable Deal; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap; Vietnam EUA Decision Delayed to 4Q22; Data Shows ARCT-154''s Potential As a Booster; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap; Vietnam Ministry of Health Continues EUA Review; Maintain Neutral and Rationalize Price Target to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-154 Showed 55% Protection Against Symptomatic COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: EUA Filed in Vietnam; ARCT-154 Could Become Arcturus'' First Approved COVID-19 Vaccine
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Arcturus Outlines Its 2022 Milestones; Our Main Focus Remains on LUNAR-COV19 Program; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-154 and ARCT-165 Show Responses to SARS-CoV-2 Variants But Overall Efficacy Still Unclear; Reducing PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; ARCT-154''s Potential EUA in Vietnam Slips Into 1Q22; Moderating PT to $47 While Maintaining Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-154 to Advance to Phase 2/3 Studies in Vietnam; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Recap: ARCT-021 Selected to Enter Phase 3 Study; Next-Gen Vaccines Enter the Clinic; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Second Next-Gen mRNA COVID-19 Vaccine, ARCT-165, Enters Phase 1/2 Study in Singapore; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Arcturus Reveals ARCT-154, a Next Generation STARR mRNA Vaccine for COVID-19; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Advancing ARCT-810 Into Phase 2 Marks an Important Milestone for the LUNAR Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Recap; Phase 3 ARCT-021 Trial Design Discussions Ongoing; Maintain Neutral Ahead of New Phase 2 Data in 2H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
First mRNA Candidate Under Ultragenyx Collaboration Enters Clinical Trials in 2H21; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Recap; Approaching Key Moment As ARCT-021 Phase 2 SARS-CoV-2 Trial Nears Top-Line Readout; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E